Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria
- Sponsor
- Pierre Fabre Pharma GmbH
- Study ID
- NCT02619929
- Status
- Completed
Conditions
- Breast Cancer
- Non-Small-Cell Lung Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Vinorelbine oral — DRUG
Study Details
The aim of this non-interventional study is to assess oral vinorelbine dose schedules (initial dose, dose increase/maintenance/reduction) applied during the initial 8 weeks of treatment under routine conditions in Germany together with the underlying reasons for the respective chosen schedules.
Key Dates
- Start date
- Feb 29, 2016
- Status verified
- Aug 2018
- Primary completion
- Mar 31, 2018
- Completion
- Mar 31, 2018
Study Design
- Enrollment
- 108 participants (actual)
Primary Outcome Measure
Rate of patients with oral vinorelbine dose increase from ≤60 to ≥80 mg/m² during the course of the study [ Time Frame: 8 weeks of treatment ]
Related Studies
- Collection of Blood From Patients With CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Harvesting Cells for Experimental Cancer TreatmentsEnrolling By Invitation · National Cancer Institute (NCI) · Bethesda, Maryland
- High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast CancerRecruiting · Carol Fabian, MD · Kansas City, Kansas
- Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer StudiesRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland